anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure provides devices, systems, and methods for capturing and analyzing behavioral and physiological data of subjects for treatment, modification, and manipulation discovery. In some embodiments, a method for classifying a drug is provided. The method includes obtaining observational data concerning an animal subject to which the drug is administered, the observational data acquired using an enclosure for the animal subject, the enclosure instrumented with at least one sensing device. The method also includes extracting features by applying the observational data to a machine-learning feature-extraction component. The method further includes predicting a class label of the drug by applying the features to a machine-learning classifier component, the machine-learning classifier component trained to predict the class label of the drug from, at least in part, the features. The method further includes providing an indication of the class label.
Olanzapine and fluoxetine capsules — Studies evaluating the individual components of olanzapine and fluoxetine capsules (olanzapine and fluoxetine) in nursing mothers are described below. Because of the potential for serious adverse reactions in nursing infants from olanzapine and fluoxetine capsules, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is recommended that women not breast-feed when receiving olanzapine and fluoxetine capsules. 

Olanzapine — In a study in lactating, healthy women, olanzapine was excreted in breast milk. Mean infant dose at steady state was estimated to be 1.8% of the maternal olanzapine dose. It is recommended that women receiving olanzapine should not breast-feed. 

Fluoxetine — Fluoxetine is excreted in human breast milk. In 1 breast milk sample, the concentration of fluoxetine plus norfluoxetine was 70.4 ng/mL. The concentration in the mother’s plasma was 295.0 ng/mL. No adverse effects on the infant were reported. In another case, an infant nursed by a mother on fluoxetine developed crying, sleep disturbance, vomiting, and watery stools. The infant’s plasma drug levels were 340 ng/mL of fluoxetine and 208 ng/mL of norfluoxetine on the 2nd day of feeding.
Loss of control (LOC) while eating (i.e., the sense that one cannot control what or how much one is eating) is prevalent among children and adolescents. LOC eating is associated with a range of physical and psychosocial health impairments, including obesity and the development of partial- and full-syndrome eating disorders. Early identification is thus critical for preventing or minimizing these adverse health outcomes. However, little is known about the development of LOC eating in children and, consequently, there is a paucity of effective interventions. Impairments in emotion regulation appear to be involved in the onset and maintenance of eating pathology in obese samples. To date, emotion regulation in youth with LOC eating problems is poorly understood, and research on underlying neurodevelopmental substrates is virtually nonexistent. The proposed research aims to characterize neurocircuitry involved in emotion regulation among 30 overweight children with LOC eating as compared to 30 overweight and 15 normal-weight controls without LOC. Participants will complete a cognitive reappraisal task whilst situated in an MRI scanner, the purpose of which is to characterize neural activity involved in reappraisal versus an emotion maintenance control condition. The proposed research aims to advance the field's understanding of the nature and correlates of LOC eating in overweight children so as to inform intervention development.
This is a 5-site randomized clinical trial of a task-oriented locomotor intervention for acute spinal cord injury (SCI). The intervention, body weight-supported treadmill training (BWSTT), partially supports the weight of the patient via an overhead lift attached to a harness. Therapists train the patient to walk on a treadmill by correcting gait deviations and manipulating sensory input that enhance control of the stance and swing phases of walking at increasingly higher speeds and less weight support. 100 patients with incomplete SCI (from below C4 to T10/11) and 100 patients with lesions at T12 to L3 will be randomly assigned to 12 weeks of conventional therapy programs for mobility versus the same intensity and duration of a combination of conventional therapy plus BWSTT. The primary outcome measures are the level of independence for ambulation and the maximal speed for walking 50 feet. Patients will be tested by masked examiners before and after the 12 weeks of therapy, and 6 and 12 months after entry into the study.
BACKGROUND: Pulmonary hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vascular remodeling, which involves aberrant proliferation and apoptosis resistance of the pulmonary arterial smooth muscle cells (PASMCs), resembling the hallmark characteristics of cancer. In cancer, the HMGB2 (high-mobility group box 2) protein promotes the pro-proliferative/antiapoptotic phenotype. However, the function of HMGB2 in PH remains uninvestigated.
METHODS: Smooth muscle cell (SMC)-specific HMGB2 knockout or HMGB2-OE (HMGB2 overexpression) mice and HMGB2 silenced rats were used to establish hypoxia+Su5416 (HySu)-induced PH mouse and monocrotaline-induced PH rat models, respectively. The effects of HMGB2 and its underlying mechanisms were subsequently elucidated using RNA-sequencing and cellular and molecular biology analyses. Serum HMGB2 levels were measured in the controls and patients with pulmonary arterial (PA) hypertension.
RESULTS: HMGB2 expression was markedly increased in the PAs of patients with PA hypertension and PH rodent models and was predominantly localized in PASMCs. SMC-specific HMGB2 deficiency or silencing attenuated PH development and pulmonary vascular remodeling in hypoxia+Su5416-induced mice and monocrotaline-treated rats. SMC-specific HMGB2 overexpression aggravated hypoxia+Su5416-induced PH. HMGB2 knockdown inhibited PASMC proliferation in vitro in response to PDGF-BB (platelet-derived growth factor-BB). In contrast, HMGB2 protein stimulation caused the hyperproliferation of PASMCs. In addition, HMGB2 promoted PASMC proliferation and the development of PH by RAGE (receptor for advanced glycation end products)/FAK (focal adhesion kinase)-mediated Hippo/YAP (yes-associated protein) signaling suppression. Serum HMGB2 levels were significantly increased in patients with PA hypertension, and they correlated with disease severity, predicting worse survival.
CONCLUSIONS: Our findings indicate that targeting HMGB2 might be a novel therapeutic strategy for treating PH. Serum HMGB2 levels could serve as a novel biomarker for diagnosing PA hypertension and determining its prognosis.
<P>PROBLEM TO BE SOLVED: To provide a composition containing a nano-particulate heterocyclic amide derivative with improved solubility in water, and preferably zafirlukast nano-particles.  <P>SOLUTION: The nano-particles have an effective average particle size of less than about 2,000 nm, and are useful for treating asthma. A multiparticulate modified release composition comprising an active ingredient delivers drugs in a pulsed or bimodal manner during operation for treating asthma. A controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, preferably, zafirlukast particles. The modified release component comprises a second population of heterocyclic amide, preferably, zafirlukast nano-particles. In the controlled release component, the combination of the immediate release component and the modified release component delivers the active ingredient during operation in the pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosion-, diffusion-, or osmosis-controlled release system.  <P>COPYRIGHT: (C)2009,JPO&INPIT
This study will conduct between April 2020 and July 2020 at Denizli State Hospital. Participants who were diagnosed as chronic non-specific neck pain by a specialist physician will include the study. They will treated at physical therapy clinic. Inclussion criteria will; participants diagnosed as non-specific neck pain by the physician and Non-spesific neck pain at least 3 months. Exclussion criteria were; participants who have had surgery or are indicated for surgery, participants who have had exercise therapy and / or physical therapy in the last 1 year with a history of trauma to the cervical region, participants who have had neck pain that develop due to a particular cause such as tumor, compression fracture, metastasis and infection. According to power analysis, 102 participant will include the study with 95% coincidence interval and 80% power. Participants will be divided into 2 groups. Randomization method will be closed envelope. Group 1 will receive Conventional Physiotherapy Programme (CP), Group 2 will receive Osteopathin Manipulative Treatment (OMT). Pain Intensity at rest and activity, psychological state( Beck Depression Inventory) and Disability level (Neck Disability Index) will assess at baseline and 3 weeks.
<P>PROBLEM TO BE SOLVED: To provide monoclonal and chimeric antibodies binding to lipoteichoic acid of gram positive bacteria, and for diagnosing, preventing and/or treating infectious diseases caused by gram positive bacteria bearing lipoteichoic acid.  <P>SOLUTION: The antibodies bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. A peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody is provided. The epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. The epitope or epitope peptide mimic provides a valuable substrate material for the production of vaccines or other therapeutic agents.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Risk Summary

Hydrocodone is present in human milk. A published lactation study reports variable concentrations of hydrocodone and hydromorphone (an active metabolite) in breast milk with administration of immediate-release hydrocodone to nursing mothers in the early post-partum period. This lactation study did not assess breastfed infants for potential adverse drug reactions. Lactation studies have not been conducted with HYSINGLA, and no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with HYSINGLA ER.

Clinical Considerations

Monitor infants exposed to HYSINGLA ER through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. The invention further relates to edible multi-layer films that dissolve in water. In particular, the edible multi-layer films have a first water-soluble film layer and one or more additional water-soluble film layers in at least partial face-to-face engagement with the first film layer.
Subjects will receive 4 cycles of neoadjuvant atezolizumab in combination with 4 cycles of CAPEOX before standard of care surgical resection. After surgery, patients who are still considered high risk for recurrence (per the treating medical oncologist) will be offered adjuvant therapy. Adjuvant therapy will consist of mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks).
In patients at high risk for ischemic stroke, clinical carotid ultrasound is often used to grade stenosis, determine plaque burden and assess stroke risk. Analysis currently requires a trained sonographer to manually identify vessel and plaque regions, which is time and labor intensive. We present a method for automatically determining bounding boxes and lumen segmentation using a Mask R-CNN network trained on sonographer assisted ground-truth carotid lumen segmentations. Automatic lumen segmentation also lays the groundwork for developing methods for accurate plaque segmentation, and wall thickness measurements in cases with no plaque. Different training schemes are used to identify the Mask R-CNN model with the highest accuracy. Utilizing a single-channel B-mode training input, our model produces a mean bounding box intersection over union (IoU) of 0.81 and a mean lumen segmentation IoU of 0.75. However, we encountered errors in prediction when the jugular vein is the most prominently visualized vessel in the B-mode image. This was due to the fact that our dataset has limited instances of B-mode images with both the jugular vein and carotid artery where the vein is dominantly visualized. Additional training datasets are anticipated to mitigate this issue.
This study aims to evaluate chest computed tomography (CT) findings in hospital patients with primary varicella pneumonia (PVP). We retrospectively analyzed CT images of 77 PVP patients using 3D Slicer, an open-source software, to model lesions and lungs. This retrospective cohort study was approved by the Institutional Review Board (Ethical Committee, Renmin Hospital, Hubei University of Medicine, Shiyan, China) and waived the requirement for written informed consent. The left lung was more frequently and severely affected in PVP, with significant differences between the 2 groups in CT involvement percentage of each lung region, except for total lung inflation. Group A showed higher median percentages of lung collapse compared to Group B. The extent of left lung involvement is a critical predictor of emphysema in PVP patients, highlighting the importance of also monitoring the right lung for more severe cases. Lower emphysema levels correspond to more collapsed and infiltrated lung segments, suggesting a more severe clinical presentation.
PROBLEM TO BE SOLVED: To obtain the subject composition by formulating plant extract(s) as active ingredient. SOLUTION: This composition, which is intended for promoting tyrosinase activity, is obtained by formulating, as active ingredients, at least one kind of extract derived from a plant selected from those belonging to the genus Malvaceae Gossypium (e.g. Algodonera), Leguminosae Erythrina (e.g. Huayruru) and Loasaceae mentzelia (e.g. Anguarate). This composition may contain an ingredient usable as a hair tonic ingredient (e.g. swertia extract, carrot extract). This composition has only to be in such a form as to be applicable to the skin or scalp such as a liquid, milky lotion or ointment, for example, being in the form of emollient lotion, moisture gel, etc. The plant extract content of the composition is pref. 0.01-5 wt.%. When this composition is to be applied to the scalp, the dose of the active ingredient is designed to be 0.1-80 mg/adult.
PURPOSE:A cosmetic, containing an extracted component of a plant belonging to the genus Coix, e.g. adlay (Coix Lachryma Jobi L.) or Coix Ma-yuen Roman., as an active constituent, capable of protecting the skin from the rash or blackening due to the sunburn by the application thereof once a day without washing the face, and usable in the form of a lotion without staining the clothing. CONSTITUTION:A cosmetic containing an extracted component from a plant body, e.g. a fruit with or without the shell thereof, belonging to the genus Coix of the family Gramineae as an active constituent. The plant body is undried or preferably dried and extracted with an extracting agent such as a water-soluble organic solvent, e.g. a 1-4C alcohol or 3-9C ketone, or a mixture thereof with water or ether.
Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
The invention discloses a traditional Chinese medicine composition for improving anoxia endurance. The traditional Chinese medicine composition comprises the following components: 10 to 30 parts of astragalus mongholicus, 20 to 40 parts of purslane speedwell herb, 15 to 25 parts of codonopsis pilosula, 10 to 30 parts of caltrop, 10 to 30 parts of asplenium antiquum makino, and 10 to 30 parts of murraya paniculata. The traditional Chinese medicine composition is in form of granula, tablet, oral liquid and capsula. The invention also discloses a preparation method of the traditional Chinese medicine composition. The preparation method comprises the following steps: adding water to decoct; concentrating; implementing alcohol precipitation; carrying out spray drying; crushing the obtained particles into dried extract powder; and adding auxiliary materials to prepare into the requested preparation. The invention also discloses application of the traditional Chinese medicine composition in preparation of medicine for improving anoxia endurance.
PURPOSE: To assess the safety and efficacy of gabapentin in reducing postoperative pain among patients undergoing scrotal surgery for male infertility by conducting a randomized, double-blind, placebo-controlled trial.
MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled trial, healthy men undergoing scrotal surgery with a single surgeon were randomized to receive either (1) gabapentin 600 mg given 2 hours preoperatively and 300 mg taken 3 times a day postoperatively for 3 days, or (2) inactive placebo. The primary outcome measure was difference in postoperative pain scores. Secondary outcomes included differences in opioid usage, patient satisfaction, and adverse events.
RESULTS: Of 97 patients screened, 74 enrolled and underwent randomization. Of these, 4 men were lost to follow-up, and 70 were included in the final analysis (35 gabapentin, 35 placebo). Both differences in initial postoperative mean pain score (-1.14, 95% CI -2.21 to -0.08, P = .035) and final mean pain score differences (-1.27, 95% CI -2.23 to -0.32, P = .0097) indicated lower gabapentin pain compared to placebo. There were no statistically significant differences in opioid usage, patient satisfaction, or adverse events.
CONCLUSIONS: These data suggest that perioperative gabapentin results in a statistically and clinically significant decrease in pain following scrotal surgery. While there was no evidence of an impact on opioid usage or patient satisfaction, given the low risk of adverse events, it may be considered as part of a multimodal pain management strategy.
FIELD: medicine. SUBSTANCE: method involves applying curative hunger therapy in cycles. At least two seven-days-long cycles with four days pause are applied. The first three days of each cycle require prohibited water drinking. Bitemporal ultra high frequency inductothermy is carried out when the cycles are over. Sodium thiosulfate and Cerebrolysin are intravenously and intramuscularly administered in the amount of 10-12 and 14-16 injections daily or each second day, respectively. EFFECT: enhanced effectiveness of treatment; long duration effect. 1 tbl
Techniques for tracking a progression of a therapeutic procedure that is performed by a patient are disclosed. A notification is received from a server computer system. This notification relates to a tracking process designed to monitor a progress of the patient in performing the therapeutic procedure. After receipt of the notification, a UI is displayed. This UI has a particular visual layout that is designed to facilitate the tracking process. In response to a particular field being selected within the UI, a secret key that de-identifies the patient is accessed. The accessed secret key and a specific image are then encrypted. As a consequence, encrypted data is generated. The encrypted data is then transmitted to the server computer system.
FIELD: microbiology, antibiotics. SUBSTANCE: antibiotic "ВМУ"-46164 isolated from fermentation product of the strain Actinomadura ATCC 53806 has empirical formula C 40 H 43 N 2 O 12 C, molecular mass 778 and shows antitumor activity. Method of antibiotic preparing involves fermentation of the strain-producer, filtration of cultural fluid, mixing filtrate with DEAE-cellulose. Mixture is cooled, DEAE-cellulose is separated by filtration, washed its with buffer and extracted with mixture of organic substances. Extract is filtered, sorbent is washed with organic solvent, filtrates were combined, water is added. Organic layer is separated and concentrated followed by isolation and purification of the end product. EFFECT: improved method of antibiotic producing and purification. 4 cl, 4 dwg, 2 tbl
Patients with cancer being treated with PI3K/AKT/mTOR inhibitors will be studied prospectively for the impact of treatment on bile acid metabolism as a function of drug-induced acute insulin resistance. Treatments will be selected by patients' treating oncologist based on standard of care.
Implant surgery placement. Tissue Level SLA Titanium implant (Straumann Standard Plus Narrow Neck CrossFit®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.